Hidradenitis suppurativa associated with Crohn?s disease and spondyloarthropathy: response to anti-TNF therapy

Abstract

An association of hidradenitis suppurativa with Crohn's disease is supported by previous repent. We here report a patient with hidradenitis suppurativa who subsequently developed peripheral arthritis, sacroiliitis, and Crohn's disease. A significant attenuation of bowel, cutaneous, and joint symptoms was achieved after treatment with monoclonal antibody against tumor necrosis factor (TNF). The pathogenetic aspects according to the literature and response to the various therapeutic measures applied are also presented.

Off-Label Dermatologic Uses of Anti-TNF-a Therapies

“…To date, five case reports [39][40][41][42][43] and one case series describe the use of infliximab in the treatment of hidradenitis suppurativa. Inflammatory bowel disease was an underlying feature in each of the five case reports.…”

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

“…As a prominent side effect, we found in the literature a case of bilateral Candida chorioretinitis in a patient with HS treated with etanercept [30]. The efficacy of infliximab in HS is consistently reported, as shown in table 4, often coinciding with Crohn's disease (cases summarized in table 4) [31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60]. In these last cases, it has been postulated that the improvement could be due to the similarity between the two diseases.…”

Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)

“…Supporting the results of this study, there are 6 additional individual case reports in the literature of complete remission of HS with infliximab treatment. [152][153][154][155][156][157] There is also one report of 6 patients with severe treatment-refractory HS who were treated with etanercept, 25 mg twice weekly. 158 All patients in this trial had significant improvement; however, no patients achieved complete remission.…”

“…87,151 Coexistence of inflammatory bowel disease was not commented on in the larger infliximab study, but 4 of the individually described patients had Crohn's disease and one patient had ulcerative colitis. [151][152][153][154][155]157 Thus it is important to consider the possibility that the observed efficacy of infliximab in these cases is a result of its effects on the underlying inflammatory bowel disease.…”